Digital Content 
NEWS #PharmaBuzz
06 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/06/3095048/0/en/Arcutis-to-Present-New-Long-Term-Results-of-ZORYVE-roflumilast-Cream-at-the-2025-Revolutionizing-Atopic-Dermatitis-Conference.html
22 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/22/3087008/0/en/Arcutis-ZORYVE-roflumilast-Topical-Foam-0-3-Approved-by-U-S-FDA-for-the-Treatment-of-Plaque-Psoriasis-in-Adults-and-Adolescents-Ages-12-and-Older.html
07 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/07/3038899/0/en/Arcutis-to-Highlight-Data-from-Phase-3-Trials-for-Scalp-and-Body-Psoriasis-and-Atopic-Dermatitis-at-the-83rd-American-Academy-of-Dermatology-Meeting.html
26 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/26/3032866/0/en/U-S-FDA-Accepts-Supplemental-New-Drug-Application-for-Arcutis-ZORYVE-roflumilast-Cream-0-05-for-the-Treatment-of-Children-Aged-2-to-5-with-Mild-to-Moderate-Atopic-Dermatitis.html
24 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/24/3031084/0/en/Arcutis-Announces-Publication-of-Positive-Data-from-INTEGUMENT-PED-Trial-Evaluating-ZORYVE-roflumilast-Cream-0-05-in-Children-2-to-5-Years-Old-with-Mild-to-Moderate-Atopic-Dermatit.html
21 Feb 2025
// BUSINESS STD
https://www.business-standard.com/markets/news/senores-pharma-rises-6-after-its-arm-inks-agreement-to-acquire-roflumilast-125022100350_1.html
Share 